TOKYO -- Takeda Pharmaceutical has begun clinical trials on three potential treatments for COVID-19 as part of a research and development team that includes U.S. peers Amgen and AbbVie Japan's biggest drugmaker said Tuesday.
The COVID R&D Alliance is recruiting up to 1,500 patients for the trials, which will take place in the U.S. over a few months.
